Ann: Letter to Shareholders, page-14

A quick reponse between drinks.

This is a good letter. It categorically states in simple terms that BIT225 is the only drug that has successfully modified immune markers and is flushing out hidden reserviours. This data is now being inspected by BP. Because BIT225 is the first and only drug to achieve this immunological benefit, I expect BP to take it on, whether that be supporting a phase 3 or taking it over.

The interpreted negative comments above regarding the inability to measure the reservious that MM brought up, is a non sequitir in the greater debate. This problem in fighting diseases is not unique to HIV. A typical example is with many cancers: "we got it all and now she'll be in remission." However, the cancer can linger on, yet it may not affect her. It may come back or it may not, but it is very likely to still be there.

Malaria etc.

BIT225's unique effect on HIV will result in the drugs advancement.

No real mention of the C19 results. IN my view this is becaus ethey stand alone from what has been tried to be conveyed in this letter.

Not long now.